Nepřihlášený uživatel
přihlásit se / registrovat

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2018; 72(2): 99–107. doi:10.14735/amgh201899.

Hepatocelulárny karcinóm na strednom Slovensku – analýza kohorty 207 pacientov v nemocnici 3. stupňa

Ľubomír Skladaný, Svetlana Adamcová-Selčanová, Vladimír Malec, Jana Badinková, Eva Pritzová, Július Janek, Stanislav Okapec

Souhrn

Úvod: Vlastnosti hepatocelulárneho karcinómu (HCC) z rôznych geografických oblastí sú odlišné. Cieľ: Analyzovať kohortu pacientov v nemocnici 3. stupňa. Metodológia: Retrospektívna analýza za sebou idúcich pacientov. Vstupné kritériá: HCC; vylučovacie kritériá: nedostatok dát; interval: roky 2007–2016. Výsledky: Súbor 207 pacientov, 95 % s cirhózou, 76 % mužov; vek 62 rokov. Etiológia hepatálneho ochorenia: Alkohol (ALD) 106 (48 %), hepatitída C 17 %, hepatitída B 13 %, nealkoholová steatohepatitída 10 %, kryptogénna 7 %, necirhotická 4 %, iná 1 %. Diagnóza prostredníctvom surveillance 24 %, bez surveillance 67 %, neznámy spôsob diagnózy 9 %. Priemer ložiska pri diagnóze SUR-HCC 5 cm, bez SUR-HCC 8,6 cm (p = 0,001). BCLC štádium: A – 30 pacientov (15 %), B – 29 %, C – 36 %, D – 20 %; BCLC podľa diagnózy (SUR-HCC vs. non-SUR-HCC): A – 15/49 (31 %) vs. 12/140 (9 %), B 43 vs. 27 %, C – 16 vs. 39 %, D – 10 vs. 25 %. Terapia: Chirurgická resekcia 17 pacientov (7 %), transplantácia pečene 14 (6 %), rádiofrekvenčná ablácia 20 (8 %), transarteriálna chemoembolizácia 60 (24 %), sorafenib 88 (35 %), suportívna starostlivosť 46 (19 %), 3 pacienti sú čakateľmi na transplantaci pečene. Priemerné prežívanie 17 (0,06–112) mesiacov, prežívanie podľa BCLC: A – 37 (2–112), B – 21 (0,6–86), C – 14 (0,06–92), D – 3 (0,06–24) mesiacov. Záver: Demografické údaje v našej kohorte sú porovnateľné s krajinami západnej Európy a Severnej Ameriky. ALD bola najčastejšou etiológiou základného ochorenia pečene, 95 % pacientov malo cirhózu. Len 24 % pacientov bolo zachytených prostredníctvom SUR-HCC, preto bol zaznamenaný výrazný posun doprava v BCLC štádiách, čo viedlo k suboptimálnej alokácii radikálnej liečby a následne aj k horšiemu prežívaniu. Súhrnne sú tieto výsledky porovnateľné s údajmi z Európy a Severnej Ameriky.

Klíčová slova

diagnóza, hepatocelulární karcinom, kohorta, léčba, přežívání, surveillance

Celý článek je dostupný po přepnutí na anglickou verzi webové stránky (v pravém horním rohu).

Literatura

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380 (9859): 2095–2128. doi: 10.1016/S0140-6736 (12) 61728-0.
2. Jemal A, Simard EP, Dorell C et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV) -associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105 (3): 175–201. doi: 10.1093/jnci/djs491.
3. Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015; 19 (2): 361–379. doi: 10.1016/j.cld.2015.01.012.
4. Archambeaud I, Auble H, Nahon P et al. Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. Liver Int 2015; 35 (7): 1872–1876. doi: 10.1111/liv.12767.
5. Omata M, Dan Y, Daniele B et al. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries. J Gastroenterol Hepatol 2002; 17 (Suppl): S40–S49.
6. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5–S16.
7. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5 Suppl 1): S27–S34.
8. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132 (7): 2557–2576.
9. Khan SA, Taylor-Robinson SD, Toledano MB el al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37 (6): 806–813.
10. De Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (3): 743–752. doi: 10.1016/j.jhep.2015.05.022.
11. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28 (5): 753–770. doi: 10.1016/j.bpg.2014.08.007.
12. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (2): 87–108. doi: 10.3322/caac.21262.
13. Bosch FX, Ribes J, Cléries R et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9 (2): 191–211.
14. World Health Organization, International Agency for Cancer Research. The global burden of disease. 2004 update. Globocan 2008. [online]. Available from: http: //www.who.int/healthinfo/global_burden_disease/GBD_report_2004 update_full.pdf.
15. Frey RS, Boldanova T. Heim MH. Ultrasound surveillance for hepatocellular carcinoma: real-life performance in a hepatology outpatient clinic. Swiss Med Wkly 2015; 145: w14200. doi: 10.4414/smw.2015.14200.
16. Harrison SA, Diehl AM. Fat and the liver: a molecular overview. Semin Gastrointest Dis 2002; 13 (1): 3–16.
17. Festi D, Colecchia A, Sacco T et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5 (1): 27–42.
18. Skladaný Ľ (ed). Infekcia vírusom hepatitídy B a hepatocelulárny karcinóm. Trendy v hepatol 2009; 3: 12–21.
19. Skladaný Ľ, Adamcová-Selčanová S, Badinková J et al. Hepatocelulárny karcinóm. Onkológia VIP 2013: 1–8.
20. Skladaný Ľ, Adamcová-Selčanová S, Pritzová E. Hepatocelulárny karcinóm BCLC-C liečený sorafenibom. Farmakoterapia 2013; 3: 20–25.
21. Adamcová-Selčanová S, Skladaný Ľ, Badinková J. Hepatocelulárny karcinóm a využitie sorafenibu. Farmakoterapie 2013; 3 (2): 78–80.
22. EL-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 2014; 60 (5): 1767–1775. doi: 10.1002/hep.27222.
23. Njei B, Rotman Y, Ditah I et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015; 61 (1): 191–199. doi: 10.1002/hep.27388.
24. Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015; 4 (1): 39–50. doi: 10.1159/000367727.
25. Sawyers CL, Abate-Shen C, Anderson KC et al. AACR cancer progress report 2013. Clin Cancer Res 2013; 19 (20 Suppl): S4–S98. doi: 10.1158/1078-0432.CCR-13-2107.
26. Benvegnù L, Gios M, Boccato S et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53 (5): 744–749.
27. Skladaný Ľ, Adamcová-Selčanová S, Dropčová A et al. Transplantácia pečene. Interná Med 2015; 3: 93–101.
28. Lang K, Danchenko N, Gondek K et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009; 50 (1): 89–99. doi: 10.1016/j.jhep.2008.07.029.
29. Arguedas MR, Chen VK, Eloubeidi MA et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98 (3): 679–690.
30. Armstrong GL, Alter MJ, McQuillan GM et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31 (3): 777–782.
31. Singal A, Volk ML, Waljee A et al. Metaanalysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30 (1): 37–47. doi: 10.1111/j.1365-2036.2009.04014.x.
32. Piscaglia F, Svegliati-Baroni G, Barchetti A et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016; 63 (3): 827–838. doi: 10.1002/hep.28368.
33. Perumpail RB, Wong RJ, Ahmed A et al. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci 2015; 60 (10): 3142–3148. doi: 10.1007/s10620-015-3821-7.
34. Farinati F, Sergio A, Baldan A et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009; 9: 33. doi: 10.1186/1471-2407-9-33.
35. Wang C, Wang H, Yang W et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 2015; 61: 1579–1590. doi: 10.1002/hep.27548.
36. Žigrai M, Skladaný Ľ, Hrušovský Š et al. Štandardný diagnostický a terapeutický postup.  Manažment liečby hepatocelulárneho karcinómu. Metodický list racionálnej farmakoterapie 2013; 16: 1–8.
37. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35 (3): 421–430.
38. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3): 1020–1022. doi: 10.1002/hep.24199.
39. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4): 908–943. doi: 10.1016/j.jhep.2011.12.001.
40. Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 2001; 48 (2): 251–259.
41. Sherman M, Bruix J, Porayko M et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56 (3): 793–796. doi: 10.1002/hep.25869.
42. Altekruse SF, McGlynn KA, Reichman ME et al. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27 (9): 1485–1491. doi: 10.1200/JCO.2008.20.7753.
43. Mittal S, Sada YH, El-Serag HB et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13 (3): 594–601. doi: 10.1016/j.cgh.2014.08. 013.
44. Sangiovanni A, Del Ninno E, Fasani P. Increas-ed survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126 (4): 1005–1014.
45. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999; 31 (Suppl 1): 25–30.
46. Velázquez RF, Rodríguez M, Navascués CA et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37 (3): 520–527.
47. Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20 (1): 65–71.
48. Chan EY, Larson AM, Fix OK et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14 (7): 956–965. doi: 10.1002/lt.21449.
49. Yuen MF, Cheng CC, Lauder IJ et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31 (2): 330–335.
50. Toyoda H, Kumada T, Osaki Y el al. Staging hepatocellular carcinoma by a novel scoring system (balad score) based on serum markers. Clin Gastroenterol Hepatol 2006; 4 (12): 1528–1536.
51. Mc Mahon BJ, Bulkow L, Harpster A el al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32 (4 Pt 1): 842–846.
52. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol 2016; 22 (1): 7–17. doi: 10.3350/cmh.2016.22.1.7.
53. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005; 7 (1): 26–34. doi: 10.1080/13651820410024 049.
54. Bialecki ES, Ezenekwe AM, Brunt EM et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4 (3): 361–368.
55. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150 (4): 835–853. doi: 10.1053/j.gastro.2015.12.041.
56. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35 (3): 519–524.
57. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5): 1208–1236.
58. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3): 1020–1022. doi: 10.1002/hep.24199.
59. Forner A, Hessheimer AJ, Isabel Real M et al. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006; 60 (2): 89–98.
60. Oliverius M, Bĕlina F, Novotný J et al. Treatment of hepatocellular carcinoma and current situation in the Czech Republic. Rozhl Chir 2007; 86 (12): 635–641.
61. Forner A, Reig ME, De Lope CR et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 (1): 61–74. doi: 10.1055/s-0030-1247133.
62. Brůha R, Drastich P, Hůlek P et al. Diagnostika a léčba hepatocelulárního karcinomu. Vnitr Lek 2005; 51 (12): 1406–1408.
63. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (1): 35–43. doi: 10.1016/S1470-2045 (08) 70284-5.
64. Suchánková G, Špičák J. Sorafenib in the treatment of hepatocellular carcinoma. Vnitr Lek 2011; 57 (5): 485–490.
65. Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7 (4): 673–687. doi: 10.4254/wjh.v7.i4.673.
66. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27 (6): 1578–1583.
67. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734–1739.
68. Marelli L, Stigliano R, Triantos C et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006; 32 (8): 594–606.
69. Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46 (3): 474–481.
70. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26): 4293–4300.
71. Kim Je, Ryoo BY, Ryu MH et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011; 68 (5): 1285–1290. doi: 10.1007/s00280-011-1616-x.
72. Llovet J, Ricci S, Mazzaferro V et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25 (Suppl 18): Abstract LBA1.
73. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11 (7): 790–800.
74. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359–E386. doi: 10.1002/ijc.29210.
75. Park JW, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35 (9): 2155–2166. doi: 10.1111/liv.12818.
76. Giannini EG, Cucchetti A, Erroi V et al. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19 (47): 8808–8821. doi: 10.3748/wjg.v19.i47.8808.
77. Weinmann A, Koch S, Niederle IM et al.Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol 2014; 48 (3): 279–289. doi: 10.1097/MCG.0b013e3182a8a793.
78. Jepsen P, Andersen MW, Villadsen GE et al. Time-trends in incidence and prognosis of hepatocellular carcinoma in Denmark: a nationwide register-based cohort study. Liver Int 2017; 37 (6): 871–878. doi: 10.1111/liv.13340.
79. Eskesen AN, Bjøro K, Aandahl EM et al. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway – a population-based cohort study. Cancer Epidemiol 2014; 38 (6): 741–747.
80. Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012; 11 (1): 18–27.
81. Leung CH, Yeoh SW, Patrick D et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21 (4): 1189–1196. doi: 10.3748/wjg.v21.i4.1189.
82. Ng M, Freeman MK, Fleming TD el al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA 2014; 311 (2): 183–192. doi: 10.1001/jama.2013.284692.
83. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387 (10027): 1513–1530. doi: 10.1016/ S0140-6736 (16) 00618-8.
84. Hoşcan Y, Yiğit F, Müderrisoğlu H. Adherence to Mediterranean diet and its relation with cardiovascular diseases in Turkish population. Int J Clin Exp Med 2015; 8 (2): 2860–2866.
85. Turati F, Trichopoulos D, Polesel J et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol 2014; 60 (3): 606–611. doi: 10.1016/j.jhep.2013.10.034.
86. Pisani P, Parkin DM, Muñoz N et al. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997; 6 (6): 387–400.
87. Bucci L, Garuti F, Lenzi B et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int 2017; 37 (2): 259–270. doi: 10.1111/liv.13204.
88. Dyson J, Jaques B, Chattopadyhay D et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60 (1): 110–117. doi: 10.1016/j.jhep.2013.08.011.
89. Szántová M. Alkohol a pečeň pohľadom hepatológa. Psychiatr prax 2013; 14 (3): 114–119.
90. Szántová M. Epidemiologický prehľad spotreby alkoholu v SR a ČR. Prakt Lék 2006; 86 (7): 374–380.
91. Szántová M. Diagnostika a liečba alkoholového poškodenia pečene. Via pract 2008; 5 (4–5): 170–172.
92. Szántová M. Alkoholová choroba pečene vo svetle nových EASL odporúčaní. Intern Med 2012; 12 (9): 433–440.
93. Szántová M. Alkoholová choroba pečene.  Alkoholizmus a drogové závislosti (protialkoholický obzor) 2013; 48 (1): 25–35.
94. Rehm J, Shield KD, Rehm M et al. Alcohol consumption, alcohol dependence and attributable burden of disease in Europe: potential gains from eff ective interventions for alcohol dependence. Toronto: CAMH 2012.
95. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289–293.
96. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (7): 417–422.
97. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United states of America. J Gastroenterol Hepatol 2001; 16 (5): 553–559.
98. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 2015; 13 (12): 2140–2151. doi: 10.1016/j.cgh.2015.08.014.
99. Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014; 9 (3): e90929. doi: 10.1371/journal.pone.0090929.
100. Fenoglio L, Serraino C, Castagna E et al. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19 (21): 3207–3216. doi: 10.3748/wjg.v19.i21.3207.
101. El-Serag HB et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44 (1): 158–166.

Kreditovaný autodidaktický test